LZTR1
LZTR1 (Leucine-zipper-like transcriptional regulator 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Prostate cancer, Endometrial cancer and 5 more.
Overview
Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates ubiquitination of Ras GTPases (M-Ras/MRAS, K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS) and Ras-like protein RIT1. Acts as a negative regulator of RAS-MAPK signalling by controlling Ras levels and decreasing Ras association with membranes.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants. Open Targets scores its association with cancer at 0.78 (direct and indirect evidence; datatypes genetic literature 0.38, literature 0.90, genetic association 0.64, somatic mutation 0.94, animal model 0.37). IntOGen calls it a driver in 4 cohorts (1 activating, 3 loss-of-function), covering Glioblastoma Multiforme, Hepatocellular Carcinoma, Prostate Adenocarcinoma, Endometrial Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · LZTR1 (Leucine-zipper-like transcriptional regulator 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Prostate cancer, Endometrial cancer and 5 more.
- 1 · What it is
LZTR1 (Leucine-zipper-like transcriptional regulator 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Prostate cancer, Endometrial cancer and 5 more.
- 2 · What goes wrong in cancer
Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates ubiquitination of Ras GTPases (M-Ras/MRAS, K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS) and Ras-like protein RIT1.
- 3 · How drugs use it
No product in this corpus aims at LZTR1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:6742 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8N653 (protein name, function text, keywords and locations (REST API)); CIViC gene LZTR1 (2 evidence items, 0 assertions, 2 variants; diseases: Schwannomatosis (GraphQL API, CC0)); Open Targets ENSG00000099949 (association with cancer (MONDO_0004992) 0.78; per-cancer scores at or above 0.5: melanoma 0.55, skin cancer 0.57, breast cancer 0.51, lung cancer 0.52 (GraphQL API, CC0)); IntOGen LZTR1 (driver in 4 cohorts (Act 1, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates ubiquitination of Ras GTPases (M-Ras/MRAS, K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS) and Ras-like protein RIT1. Acts as a negative regulator of RAS-MAPK signalling by controlling Ras levels and decreasing Ras association with membranes. Location: Endomembrane system; Recycling endosome; Golgi apparatus (UniProt). Locus 22q11.21 (HGNC).
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Prostate cancer: IntOGen driver in 1 cohort (PRAD)
- Endometrial cancer: IntOGen driver in 1 cohort (UCEC)
- Skin cancer: Open Targets association 0.57 with skin cancer (MONDO_0002898)
- Lung cancer: Open Targets association 0.52 with lung cancer (MONDO_0008903)
- Breast cancer: Open Targets association 0.51 with breast cancer (MONDO_0007254)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Schwannomatosis.
Latest papers
topQuery for this target: (TITLE:"LZTR1" OR ABSTRACT:"LZTR1" OR TITLE:"leucine zipper like post translational regulator 1" OR ABSTRACT:"leucine zipper like post translational regulator 1" OR TITLE:"Leucine-zipper-like transcriptional regulator 1" OR ABSTRACT:"Leucine-zipper-like transcriptional regulator 1" OR TITLE:"LZTR-1" OR ABSTRACT:"LZTR-1" OR TITLE:"BTBD29" OR ABSTRACT:"BTBD29") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LZTR1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetMECOM
Shares Lung cancer (all types), Skin cancer (all types), Endometrial cancer, Breast cancer (all types).
- TargetCLTCL1
Shares Lung cancer (all types), Skin cancer (all types), Hepatocellular carcinoma, Breast cancer (all types).
- TargetABL2
Shares Lung cancer (all types), Skin cancer (all types), Endometrial cancer, Breast cancer (all types).
- TargetCBLB
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetAFF4
Shares Lung cancer (all types), Skin cancer (all types), Hepatocellular carcinoma, Breast cancer (all types).
- TargetAFDN
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetATP2B3
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetZBTB16
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.